Valo to Participate in Credit Suisse 2021 Healthcare Innovators Series: The Intersection of Drug Discovery, Drug Development and Artificial Intelligence

CEO Berry to take part in panel: AI/Software and the Impact on Drug Discovery and Development

BOSTON, March 18, 2021 /​PRNewswire/​— Valo Health LLC (Valo), the tech­nol­o­gy com­pa­ny that is using human-cen­tric data and machine learn­ing com­pu­ta­tion to trans­form and accel­er­ate the drug dis­cov­ery and devel­op­ment process, today announced that David Berry, Ph.D., founder and Chief Exec­u­tive Offi­cer of Valo will par­tic­i­pate in the Cred­it Suisse Health­care Inno­va­tors Series: The Inter­sec­tion of Drug Dis­cov­ery, Drug Devel­op­ment and Arti­fi­cial Intelligence.

The pan­el, titled: AI/​Software and the Impact on Drug Dis­cov­ery and Devel­op­ment, will take place vir­tu­al­ly on Tues­day, March 23, 2021 at 10:00 AM ET will exam­ine how AI can change the way drugs are devel­oped and where the indus­try is expect­ed to be in five years.

About Valo
Valo Health, LLC (Valo) is a tech­nol­o­gy com­pa­ny that is using human-cen­tric data and machine learn­ing com­pu­ta­tion to trans­form the drug dis­cov­ery and devel­op­ment process. As a dig­i­tal­ly native com­pa­ny, Valo is the first to ful­ly inte­grate human-cen­tric data across the entire drug devel­op­ment life­cy­cle into a sin­gle uni­fied archi­tec­ture, there­by accel­er­at­ing the dis­cov­ery and devel­op­ment of life-chang­ing drugs while simul­ta­ne­ous­ly reduc­ing the cost, time, and fail­ure rate. The com­pa­ny’s Opal Com­pu­ta­tion­al Plat­form™, a ful­ly inte­grat­ed, com­pu­ta­tion­al, end-to-end drug devel­op­ment plat­form, offers a unique approach to ther­a­peu­tic devel­op­ment that enables Valo to advance a robust pipeline of can­di­dates across car­dio­vas­cu­lar dis­ease, oncol­o­gy, and neu­rode­gen­er­a­tion. Found­ed by Flag­ship Pio­neer­ing and head­quar­tered in Boston, MA, Valo has offices in Lex­ing­ton, MA, San Fran­cis­co, CA, Prince­ton, NJ, and in Bran­ford, CT. To learn more, vis­it www​.val​o​health​.com.

Con­tacts:
Investors: Graeme Bell, Chief Finan­cial Offi­cer
gbell@​valohealth.​com

Media: Jen­nifer Han­ley, VP Cor­po­rate Com­mu­ni­ca­tions
jhanley@​valohealth.​com

Other
Press